XOMA Competitors

XOMA (NASDAQ:XOMA) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares XOMA and Amgen's revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

57.2% of XOMA shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 9.9% of XOMA shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for XOMA and Amgen, as provided by MarketBeat.com.

XOMA currently has a consensus target price of $46.00, suggesting a potential upside of 29.80%. Amgen has a consensus target price of $261.1429, suggesting a potential upside of 0.77%. Given XOMA's stronger consensus rating and higher probable upside, analysts plainly believe XOMA is more favorable than Amgen.

Profitability

This table compares XOMA and Amgen's net margins, return on equity and return on assets.

Risk and Volatility

XOMA has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Summary

Amgen beats XOMA on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and XOMA (NASDAQ:XOMA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Risk & Volatility

Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, XOMA has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Gilead Sciences and XOMA, as provided by MarketBeat.com.

Gilead Sciences currently has a consensus price target of $97.68, suggesting a potential upside of 47.51%. XOMA has a consensus price target of $46.00, suggesting a potential upside of 29.80%. Given Gilead Sciences' higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than XOMA.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 57.2% of XOMA shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 9.9% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Gilead Sciences and XOMA's gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and XOMA's net margins, return on equity and return on assets.

Summary

Gilead Sciences beats XOMA on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and XOMA (NASDAQ:XOMA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 57.2% of XOMA shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 9.9% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and XOMA, as reported by MarketBeat.

Vertex Pharmaceuticals currently has a consensus price target of $293.2083, indicating a potential upside of 33.24%. XOMA has a consensus price target of $46.00, indicating a potential upside of 29.80%. Given Vertex Pharmaceuticals' higher probable upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than XOMA.

Profitability

This table compares Vertex Pharmaceuticals and XOMA's net margins, return on equity and return on assets.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, XOMA has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and XOMA's revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats XOMA on 11 of the 15 factors compared between the two stocks.

XOMA (NASDAQ:XOMA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Valuation and Earnings

This table compares XOMA and Regeneron Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares XOMA and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for XOMA and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

XOMA currently has a consensus target price of $46.00, suggesting a potential upside of 29.80%. Regeneron Pharmaceuticals has a consensus target price of $644.1739, suggesting a potential upside of 27.70%. Given XOMA's stronger consensus rating and higher possible upside, equities analysts clearly believe XOMA is more favorable than Regeneron Pharmaceuticals.

Volatility & Risk

XOMA has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Insider & Institutional Ownership

57.2% of XOMA shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 9.9% of XOMA shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats XOMA on 11 of the 15 factors compared between the two stocks.

XOMA (NASDAQ:XOMA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Volatility & Risk

XOMA has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares XOMA and Biogen's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for XOMA and Biogen, as reported by MarketBeat.com.

XOMA currently has a consensus price target of $46.00, suggesting a potential upside of 29.80%. Biogen has a consensus price target of $303.3103, suggesting a potential upside of 11.07%. Given XOMA's stronger consensus rating and higher probable upside, equities research analysts plainly believe XOMA is more favorable than Biogen.

Institutional and Insider Ownership

57.2% of XOMA shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 9.9% of XOMA shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares XOMA and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats XOMA on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and XOMA (NASDAQ:XOMA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, XOMA has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 57.2% of XOMA shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, 9.9% of XOMA shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and XOMA, as reported by MarketBeat.com.

Alexion Pharmaceuticals currently has a consensus target price of $153.4286, indicating a potential downside of 7.87%. XOMA has a consensus target price of $46.00, indicating a potential upside of 29.80%. Given XOMA's stronger consensus rating and higher probable upside, analysts plainly believe XOMA is more favorable than Alexion Pharmaceuticals.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and XOMA's revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and XOMA's net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats XOMA on 11 of the 15 factors compared between the two stocks.